Cingulate Inc. (NASDAQ:CING) announced the successful completion of its final FDA-required study for CTx-1301 (dexmethylphenidate) aimed at treating Attention Deficit Hyperactivity Disorder (ADHD).
Podcast: How do the five love languages hold up to empirical research? How does gender equality vary by country globally? Tune in to hear highlights from last year’s most popular research.